Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Rebecca Meshaw"'
Autor:
Yutian Feng, Rebecca Meshaw, Darryl McDougald, Zhengyuan Zhou, Xiao-Guang Zhao, Stephen A. Jannetti, Robert E. Reiman, Erica Pippen, Robin Marjoram, Jeffrey L. Schaal, Ganesan Vaidyanathan, Michael R. Zalutsky
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-13 (2022)
Abstract Radiopharmaceutical therapy (RPT) is an attractive strategy for treatment of disseminated cancers including those overexpressing the HER2 receptor including breast, ovarian and gastroesophageal carcinomas. Single-domain antibody fragments (s
Externí odkaz:
https://doaj.org/article/d70520eee8e345729165a858843f0fb1
Autor:
Yutian Feng, Rebecca Meshaw, Xiao-Guang Zhao, Stephen Jannetti, Ganesan Vaidyanathan, Michael R. Zalutsky
Publikováno v:
Journal of Nuclear Medicine. 64:124-130
Autor:
Ganesan Vaidyanathan, Irina V. Balyasnikova, Darryl McDougald, Rebecca Meshaw, Michael R. Zalutsky, Zhengyuan Zhou
Publikováno v:
Nuclear Medicine and Biology. :24-35
Introduction Labeling single domain antibody fragments (sdAbs) with 18F is an attractive strategy for immunoPET. Earlier, we developed a residualizing label, N-succinimidyl 3-((4-(4-fluorobutyl)-1H-1,2,3-triazol-1-yl)methyl)-5-(guanidinomethyl)benzoa
Publikováno v:
Journal of Nuclear Medicine. 62:1624-1630
1624 Objectives: Positive allosteric modulators of muscarinic acetylcholine receptor subtype 4 (M4) have been identified as promising activators for the treatment of neurological disorders and neurodegenerative diseases, including schizophrenia, Alzh
Autor:
Zhengyuan, Zhou, Darryl, McDougald, Rebecca, Meshaw, Irina, Balyasnikova, Michael R, Zalutsky, Ganesan, Vaidyanathan
Publikováno v:
Nucl Med Biol
INTRODUCTION: Labeling single domain antibody fragments (sdAbs) with (18)F is an attractive strategy for immunoPET. Earlier, we developed a residualizing label, N-succinimidyl 3-((4-(4-fluorobutyl)-1H-1,2,3-triazol-1-yl)methyl)-5-(guanidinomethyl)ben
Autor:
Yutian Feng, Samantha Sarrett, Rebecca Meshaw, Ganesan Vaidyanathan, Brian Zeglis, Michael Zalutsky
Publikováno v:
Nuclear Medicine and Biology. :S32
Publikováno v:
J Nucl Med
Single-domain antibody fragments (sdAbs) are promising vectors for immuno-PET; however, better methods for labeling sdAbs with (18)F are needed. Herein, we evaluate a site-specific strategy using an (18)F residualizing motif and the anti–epidermal
Autor:
Rebecca Meshaw, Zhengyuan Zhou, Darryl McDougald, Yutian Feng, Michael R. Zalutsky, Ganesan Vaidyanathan
Publikováno v:
Nucl Med Biol
INTRODUCTION: As a consequence of their small size, high stability and high affinity, single domain antibody fragments (sdAb) are appealing targeting vectors for radiopharmaceutical development. With sdAbs binding to internalizing receptors like HER2